The immunopharmacologic and anti-inflammatory properties of RMI 9563 with special reference to its effect on the complement system.
The immunopharmacology of RMI 9563 - bis[3-(diethylamino)propyl]fluoranthene-3,9-dicarboxylate dihydrochloride--has been described. The compound, when given parenterally, inhibited several cell-mediated immune responses (EAE, tuberculin skin reaction, adjuvant arthritis) in rats, enhanced IgM and IgG antibody-producing cells in mice, and displayed anti-inflammatory activity in several models (carrageenan paw edema, adjuvant arthritis, direct passive Arthus reaction--a model of inflammation that is immunologically induced and complement-dependent). RMI 9563 suppressed the activation of complement in vitro by the selective inhibition of C1 esterase.
D000818:Animals; D000893:Anti-Inflammatory Agents; D000917:Antibody Formation / Q000187:drug effects*; D001169:Arthritis, Experimental / Q000517:prevention & control; D001183:Arthus Reaction / Q000276:immunology; D002351:Carrageenan / Q000037:antagonists & inhibitors; D003169:Complement Inactivator Proteins; D003165:Complement System Proteins / Q000096:biosynthesis*; D003998:Dicarboxylic Acids; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology; D005260:Female; D005449:Fluorenes; D006461:Hemolysis / Q000187:drug effects; D007111:Immunity, Cellular / Q000187:drug effects*; D051379:Mice; D051381:Rats; D012756:Sheep / Q000276:immunology; D014374:Tuberculin Test
D000893:Anti-Inflammatory Agents; D003169:Complement Inactivator Proteins; D003998:Dicarboxylic Acids; D005449:Fluorenes; C016919:RMI 9563; D002351:Carrageenan; D003165:Complement System Proteins